Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.
Also in This 8-page Issue: President Bush Nominates EPA Administrator Michael Leavitt for HHS Secretary.
NCI Selects 15 Awardees to Operate the Cancer Information Service.
American Legacy Foundation Says Group is Fighting For Its Survival.
Funding Opportunities Listed.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- How will FDA regulate psychedelics?
- The future of oncology: Early-career scientists need mentorship and a new academic model
- The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long” - OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care









